Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP.
A patient with disseminated osseous metastases due to breast cancer reported multifocal pain. Because of persisting pain after a first cycle of chemotherapy, 1,295 MBq Re-186 HEDP was administered intravenously. Excellent pain relief was observed. Subsequently, the patient received further combined chemotherapy and Re-186 HEDP therapy and remained pain free. Tc-99m MDP bone imaging showed a significant regression of osseous metastases. It may be speculated that the combination of Re-186 HEDP and chemotherapy results in significantly increased palliation of metastatic bone disease.
Palmedo
H
H
Department of Nuclear Medicine, University of Bonn, Germany.
Grünwald
F
F
Wagner
U
U
Köhler
S
S
Krebs
D
D
Biersack
H J
HJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D012211:Rhenium / Q000627:therapeutic use*; D013669:Technetium Tc 99m Medronate
D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012211:Rhenium; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate